Torch™ has not yet been submitted to FDA for review of its Indications for Use and is therefore NOT suitable for clinical use.
Voximetry is a Healthtech company committed to personalized patient RPT care. Torch™ Plan Assessment and Treatment Planning is designed to accurately predict efficacy and adverse effects of radiopharmaceutical therapy through personalized treatment plans. Using Torch, physicians can prescribe personalized treatment plan objectives for absorbed dose to tumors and maximum limits for non-target critical structures and support them in achieving their treatment objectives.
1/13/22 - Dr. Chuck Stearns Joins Voximetry as Senior Advanced Development Engineer: Image Processing Algorithms. Read More>>
1/11/22 - Voximetry Incorporated has been awarded nearly $400,000 from the U.S. National Cancer Institute, National Institutes of Health, Department of Health and Human Services to improve the quantitative accuracy of nuclear medicine SPECT/CT images used in the planning and assessment of Radiopharmaceutical Therapy (RPT). Read More>>
3/8/2021 - Read More>>
1/19/2021 - Voximetry continues its momentum with hiring of Chief Executive Officer Dr. Sue Wallace. Read More>>
11/9/2020 - Voximetry and the Imaging and Radiation Oncology Core (IROC) have reached agreement to evaluate the role of dosimetry in alpha- and beta-emitting Radiopharmaceutical Therapy (RPT) clinical trials. Read more>>
11/3/2020 - Sankara Hari Gopalakrishnan has joined Voximetry as a Senior Software Engineer for Image Processing and Optimization Algorithms. He will be advancing Voximetry's Torch™ software in the areas of deformable registration, contour propagation, and optimization. Read more>>
10/15/2020 - Voximetry has been awarded a Phase II Small Business Innovation Research (SBIR) grant valued at $1.8 million from the National Cancer Institute (NCI). This award will assist Voximetry in commercializing its Torch™ software for RPT treatment planning. Read more>>
Copyright © 2021 Voximetry Incorporated - All Rights Reserved.